Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported

Rhea-AI Filing Summary

Puma Biotechnology Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class.

The filing states Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report ownership separately in reliance on SEC Release No. 34-39538. The report is signed by Ashley Grim, Head of Global Fund Administration.

Insights

Institutional Ownership Analyst

Vanguard disaggregated holdings to subsidiaries; reported zero beneficial ownership for PBYI.

The filing states 0 shares and 0% beneficial ownership as reported by The Vanguard Group following an internal realignment on January 12, 2026. This reflects a reporting change rather than a disclosed market trade.

Subsequent filings from the named subsidiaries may show separate positions; timing and amounts for any such reports are not included here.

Securities Compliance Counsel

Filing cites SEC Release No. 34-39538 to justify disaggregation of holdings.

The Schedule 13G/A explicitly references SEC Release No. 34-39538 (January 12, 1998) and states certain subsidiaries will report beneficial ownership separately from The Vanguard Group. The statement follows the cited release's disaggregation allowance.

Signatory is Ashley Grim with a signature date of 03/27/2026; no proceeds, transactions, or subsidiary amounts are disclosed here.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Puma Biotechnology Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74587V107

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74587V107

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Puma Biotechnology Inc
(b)	Address of issuer's principal executive offices: 10880 Wilshire Blvd, Suite 2150, Los Angeles, CA, 90024
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/27/2026

FAQ

What does Puma Biotechnology (PBYI) Schedule 13G/A filed by Vanguard report?

It reports 0 shares beneficially owned, equal to 0% of Common Stock. The filing states Vanguard completed an internal realignment on January 12, 2026, and certain subsidiaries will report ownership separately under SEC Release No. 34-39538.

Does the filing show Vanguard sold Puma Biotechnology (PBYI) shares?

No—this filing reports a change in reporting structure, not a disclosed sale. It explains an internal realignment and disaggregation under SEC Release No. 34-39538, with Vanguard reporting 0 shares post-realignment.

Who signed the Schedule 13G/A for Puma Biotechnology (PBYI) on behalf of Vanguard?

The filing is signed by Ashley Grim, identified as Head of Global Fund Administration, with a signature date of 03/27/2026. The signature affirms the reporting statements in this amendment.

When did The Vanguard Group's internal realignment mentioned in the filing occur?

The filing states the internal realignment occurred on January 12, 2026. It cites SEC Release No. 34-39538 as the basis for reporting certain subsidiaries separately after that date.

Will other Vanguard entities report Puma Biotechnology (PBYI) holdings separately after this filing?

Possibly; the amendment says certain Vanguard subsidiaries or business divisions will report beneficial ownership separately. Specific subsidiary holdings or amounts are not disclosed in this excerpt.